3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction

3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction

Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms, and new bioma...

Full description

Bibliographic Details
Main Authors: Huan Zhang, Huanyao Gao, Yayun Gu, August John, Lixuan Wei, Minhong Huang, Jia Yu, Adeyemi A. Adeosun, Richard M. Weinshilboum, Liewei Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
PARP inhibitor
prostate cancer
CRISPR screen
TBL1XR1
SMC3
γH2AX
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.999302/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.999302/full

Similar Items